ARS Pharmaceuticals Forecast, price target & analysts
ARS Pharmaceuticals Target price 2026 - Analyst rating & recommendation
ARS Pharmaceuticals Classifications & Recommendation
ARS Pharmaceuticals Price Target
| Target Price | $29.58 |
| Price | $4.12 |
| Potential |
617.96%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target ARS Pharmaceuticals 2027 .
The average ARS Pharmaceuticals target price is $29.58.
This is
617.96%
register free of charge
$34.65
741.02%
register free of charge
$15.15
267.72%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend ARS Pharmaceuticals to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ARS Pharmaceuticals stock has an average upside potential 2027 of
617.96%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 84.28 | 132.43 |
| 5.46% | 57.13% | |
| EBITDA Margin | -211.97% | -11.05% |
| 6,241.38% | 94.79% | |
| Net Margin | -203.25% | -141.69% |
| 2,364.98% | 30.29% |
6 Analysts have issued a sales forecast ARS Pharmaceuticals 2026 . The average ARS Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an ARS Pharmaceuticals EBITDA forecast 2026. The average ARS Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-179m | 5,894.97% |
|---|---|---|
| 2026 |
$-14.6m
91.81%
unlock
|
|
EBITDA Margin
| 2025 | -211.97% | 6,241.38% |
|---|---|---|
| 2026 |
-11.05%
94.79%
unlock
|
|
6 ARS Pharmaceuticals Analysts have issued a net profit forecast 2026. The average ARS Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.74 | -1.89 |
| 2,275.00% | 8.62% | |
| P/E | negative | |
| EV/Sales | 2.88 |
6 Analysts have issued a ARS Pharmaceuticals forecast for earnings per share. The average ARS Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
ARS Pharmaceuticals...
Current ARS Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jun 25 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 28 2026 |
| Roth Capital |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 08 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jun 25 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
Roth Capital:
Locked
➜
Locked
|
Sep 04 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Jan 14 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 08 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
